79
Views
4
CrossRef citations to date
0
Altmetric
Editorials

Bioengineered factor Xa as a potential new strategy for hemophilia therapy

Pages 121-123 | Published online: 10 Jan 2014
 

Financial & competing interests disclosure

RM Camire is supported by NIH grants P01 HL-74124 Project 2, R01 HL-88010 and research funding from Pfizer. The author also receives royalties from Pfizer for technology related to FXa. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 435.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.